WAVE Life Sciences Ltd.
WVE
$6.73
-$0.06-0.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 188.23% | -115.60% | -10.92% | -3.02% | 2,245.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 188.23% | -115.60% | -10.92% | -3.02% | 2,245.12% |
| Cost of Revenue | 31.02% | 30.20% | 21.25% | 7.97% | 9.64% |
| Gross Profit | 879.25% | -378.13% | -84.70% | -15.84% | 83.18% |
| SG&A Expenses | 18.09% | 14.58% | 16.56% | 10.74% | -0.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.32% | 25.62% | 19.99% | 8.75% | 6.55% |
| Operating Income | 222.94% | -1,538.23% | -49.09% | -13.78% | 57.11% |
| Income Before Tax | 279.95% | -1,039.62% | -56.00% | -15.15% | 62.22% |
| Income Tax Expenses | -- | -- | -- | -- | -100.00% |
| Earnings from Continuing Operations | 279.95% | -951.90% | -56.00% | -15.15% | 62.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 279.95% | -951.90% | -56.00% | -15.15% | 62.81% |
| EBIT | 222.94% | -1,538.23% | -49.09% | -13.78% | 57.11% |
| EBITDA | 235.64% | -1,216.24% | -53.25% | -15.82% | 58.14% |
| EPS Basic | 222.12% | -806.06% | -27.04% | 9.09% | 68.11% |
| Normalized Basic EPS | 222.11% | -850.77% | -27.02% | 9.06% | 67.60% |
| EPS Diluted | 212.24% | -812.12% | -27.04% | 9.09% | 67.14% |
| Normalized Diluted EPS | 214.46% | -858.59% | -27.02% | 9.06% | 67.60% |
| Average Basic Shares Outstanding | 47.31% | 25.03% | 22.82% | 26.67% | 16.63% |
| Average Diluted Shares Outstanding | 57.16% | 23.92% | 22.82% | 26.67% | 16.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |